AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19635216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine infusion under general anesthesia and 0.01 mg/kg ketamine for 24 hours post-surgery
Number of subjects: 200
Study 19635216 — intervention group
Group type: COMPARATOR
Intervention: Normal saline only (control group)
Number of subjects: 200
Study 16947094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent diazepam prophylaxis (n = 68)
Number of subjects: 139
Study 16947094 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (n = 71)
Number of subjects: 139
Study 15587293 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational strategy promoting participation of three phases (homework, discussion in small groups, plenary session)
Number of subjects: 0
Study 15587293 — intervention group
Group type: COMPARATOR
Intervention: Educational strategy promoting participation of two phases (homework and plenary session)
Number of subjects: 0
Study 15587293 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 0
Study 11006205 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal intracardiac embryo puncture
Number of subjects: 149
Study 9348834 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse education intervention
Number of subjects: 88
Study 9348834 — intervention group
Group type: COMPARATOR
Intervention: Control group (promotion workshop without substance abuse component)
Number of subjects: 88
Study 1490448 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral volumetric computed tomography (SVCT)
Number of subjects: 100
Study 1490448 — intervention group
Group type: COMPARATOR
Intervention: Dynamic incremental computed tomography (DICT)
Number of subjects: 100
Study 3895889 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 145
Study 3895889 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin-sulfisoxazole
Number of subjects: 145
Study 31294485 — intervention group
Group type: EXPERIMENTAL
Intervention: Refutation response
Number of subjects: 915
Study 31294485 — intervention group
Group type: EXPERIMENTAL
Intervention: Attack response
Number of subjects: 915
Study 31294485 — intervention group
Group type: EXPERIMENTAL
Intervention: Denial response
Number of subjects: 915
Study 31294485 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumor responses (refutation, denial, attack the attacker)
Number of subjects: 915
Study 30475868 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian additive regression tree model predicting university GPA
Number of subjects: 109
Study 28440024 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of 2 reduced-diameter implants with locator-analog attachments
Number of subjects: 25
Study 28440024 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of 4 reduced-diameter implants with locator-analog attachments
Number of subjects: 25
Study 28440024 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of 2 implants
Number of subjects: 25
Study 25486131 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release phentermine and topiramate
Number of subjects: 328
Study 25486131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 25486131 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 328
Study 24048296 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice nurse led telephone coaching intervention (8 telephone and 1 face to face coaching episodes per patient)
Number of subjects: 473
Study 24048296 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (control group)
Number of subjects: 473
Study 20068559 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (1 g tablet after breakfast and 1 g tablet after dinner for 24 weeks)
Number of subjects: 0
Study 20068559 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (control group)
Number of subjects: 0
Study 18855809 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site primary care
Number of subjects: 582
Study 16642607 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with routine western medicine (Mannitol, Nifedipine, and Ceftriaxone sodium) for 10 days, starting 9 days after operation.
Number of subjects: 100
Study 16642607 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine (Mannitol, Nifedipine, and Ceftriaxone sodium).
Number of subjects: 100
Study 12841698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundal pressure during cesarean delivery
Number of subjects: 84
Study 12841698 — intervention group
Group type: COMPARATOR
Intervention: No fundal pressure during cesarean delivery
Number of subjects: 84
Study 10493335 — intervention group
Group type: EXPERIMENTAL
Intervention: PncD vaccine (3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F, and 23F conjugated to diphtheria toxoid)
Number of subjects: 40
Study 10493335 — intervention group
Group type: EXPERIMENTAL
Intervention: PncT vaccine (3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F, and 23F conjugated to tetanus protein)
Number of subjects: 40
Study 10493335 — intervention group
Group type: EXPERIMENTAL
Intervention: PncD and PncT vaccines
Number of subjects: 40
Study 8905945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenous (group O)
Number of subjects: 12
Study 8905945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ondansetron, group C)
Number of subjects: 12
Study 1831016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg IV)
Number of subjects: 71
Study 1831016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 71
Study 7016322 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan (L-PAM)
Number of subjects: 1548
Study 7016322 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan (L-PAM) + 5-FU (PF)
Number of subjects: 1548
Study 7016322 — intervention group
Group type: EXPERIMENTAL
Intervention: PF + Methotrexate (MTX) (PMF)
Number of subjects: 1548
Study 7016322 — intervention group
Group type: COMPARATOR
Intervention: PF
Number of subjects: 1548
Study 7016322 — intervention group
Group type: EXPERIMENTAL
Intervention: PMF
Number of subjects: 1548
Study 31183750 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training with daily protein supplementation for 10 weeks
Number of subjects: 22
Study 31183750 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 31579326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided rectus sheath block with 0.25% ropivacaine (0.5 ml/kg per side)
Number of subjects: 76
Study 31579326 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic infiltration of the surgical field with 0.5% ropivacaine (0.4 ml/kg)
Number of subjects: 76
Study 31579326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 27935465 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis (performed at least 10 times a day)
Number of subjects: 60
Study 27935465 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 25467200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lumbopelvic motor control and progressive hip strengthening exercise therapy programme
Number of subjects: 80
Study 25467200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic motor control exercise programme
Number of subjects: 80
Study 23150693 — intervention group
Group type: EXPERIMENTAL
Intervention: Active subjects
Number of subjects: 31
Study 23150693 — intervention group
Group type: COMPARATOR
Intervention: Sedentary subjects
Number of subjects: 31
Study 22046719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive countermeasures (information removal technique)
Number of subjects: 23
Study 22046719 — intervention group
Group type: COMPARATOR
Intervention: No countermeasure (control group)
Number of subjects: 23
Study 19196472 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyGlycoplex (PGX) supplementation at a maximum dose of 10 g per day for 21 days
Number of subjects: 0
Study 19196472 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyGlycoplex (PGX) supplementation
Number of subjects: 0
Study 19196472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17027571 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 70
Study 12751275 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified orange juice
Number of subjects: 16
Study 12751275 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice without calcium fortification
Number of subjects: 16
Study 12751275 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no juice)
Number of subjects: 16
Study 11206864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg)
Number of subjects: 0
Study 11206864 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (5 mg)
Number of subjects: 0
Study 11206864 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (10 mg)
Number of subjects: 0
Study 11206864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8455664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus metopimazine
Number of subjects: 30
Study 8455664 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron alone
Number of subjects: 30
Study 3095111 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 3 X 40 mg X d‐1
Number of subjects: 12
Study 3095111 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 3 X 80 mg X d‐1
Number of subjects: 12
Study 3095111 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 3 X 120 mg X d‐1
Number of subjects: 12
Study 3095111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30077288 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX (dexmedetomidine)
Number of subjects: 40
Study 30077288 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil (control group)
Number of subjects: 40
Study 27379911 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation (5 mg salbutamol sulfate, 1 mL saline + 1 mL salbutamol, nebulized for 10 minutes)
Number of subjects: 23
Study 27379911 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation (2 mL nebulized normal saline)
Number of subjects: 23
Study 23970206 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/nevirapine (group 1)
Number of subjects: 119
Study 23970206 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/lopinavir/ritonavir (group 2)
Number of subjects: 119
Study 23970206 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/zidovudine (group 3)
Number of subjects: 119
Study 23970206 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/efavirenz (group 4)
Number of subjects: 119
Study 22436797 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 0.5 mg every 12 hours (n = 51)
Number of subjects: 101
Study 22436797 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 hours (n = 50)
Number of subjects: 101
Study 20513750 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy titration to maximal tolerated dose
Number of subjects: 138
Study 18791928 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCC (3.0 g/day for 4 weeks)
Number of subjects: 21
Study 18791928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15908270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol infusion
Number of subjects: 36
Study 15908270 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 36
Study 15908270 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative therapy
Number of subjects: 36
Study 15908270 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis
Number of subjects: 36
Study 15908270 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 36
Study 12050274 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/d)
Number of subjects: 48
Study 12050274 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg/d)
Number of subjects: 48
Study 12050274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10505899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visiting programme for vulnerable families with newborns
Number of subjects: 181
Study 8648287 — intervention group
Group type: EXPERIMENTAL
Intervention: Reorganizing clue provided post-learning to categorize a second, interfering list.
Number of subjects: 0
Study 8648287 — intervention group
Group type: EXPERIMENTAL
Intervention: Reorganizing clue provided post-learning during serial recall of an initial list of letters.
Number of subjects: 0
Study 1306421 — intervention group
Group type: EXPERIMENTAL
Intervention: Celaskon effervescens Spofa at a dose of 500 mg/day/person
Number of subjects: 140
Study 3882063 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin
Number of subjects: 230
Study 3882063 — intervention group
Group type: COMPARATOR
Intervention: azathioprine
Number of subjects: 230
Study 30630451 — intervention group
Group type: EXPERIMENTAL
Intervention: Graf's fixation device
Number of subjects: 117
Study 30630451 — intervention group
Group type: COMPARATOR
Intervention: Manual fixation by parents
Number of subjects: 117
Study 30424770 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative high PEEP (8 cmH2O) with systematic recruitment maneuvers and ultra-protective ventilation during CPB.
Number of subjects: 494
Study 30424770 — intervention group
Group type: COMPARATOR
Intervention: Low levels of PEEP (2 cmH2O) with no recruitment maneuvers and continuous positive airway pressure during CPB (2 cmH2O).
Number of subjects: 494
Study 26704806 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrotomy
Number of subjects: 0
Study 26704806 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopy
Number of subjects: 0
Study 24734247 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Number of subjects: 473
Study 21566200 — intervention group
Group type: EXPERIMENTAL
Intervention: CS‐0777 0.1 mg
Number of subjects: 24
Study 21566200 — intervention group
Group type: EXPERIMENTAL
Intervention: CS‐0777 0.3 mg
Number of subjects: 24
Study 21566200 — intervention group
Group type: EXPERIMENTAL
Intervention: CS‐0777 1.0 mg
Number of subjects: 24
Study 21566200 — intervention group
Group type: EXPERIMENTAL
Intervention: CS‐0777 2.5 mg
Number of subjects: 24
Study 21566200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21566200 — intervention group
Group type: EXPERIMENTAL
Intervention: CS‐0777 (all doses)
Number of subjects: 24
Study 21566200 — intervention group
Group type: EXPERIMENTAL
Intervention: CS‐0777 (2.5 mg)
Number of subjects: 24
Study 20332306 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3608
Study 20332306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3608
Study 20332306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (Finasteride and Placebo)
Number of subjects: 3608
Study 18541793 — intervention group
Group type: EXPERIMENTAL
Intervention: TIA alone as a qualifying event
Number of subjects: 57
Study 18541793 — intervention group
Group type: COMPARATOR
Intervention: Stroke alone as a qualifying event
Number of subjects: 57
Study 18541793 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cerebral infarct on baseline neuroimaging
Number of subjects: 57
Study 15955184 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Search AV (ESAV) parameters
Number of subjects: 30
Study 15955184 — intervention group
Group type: COMPARATOR
Intervention: Default Search AV (KSAV) parameters
Number of subjects: 30
Study 15955184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (ESAV and KSAV)
Number of subjects: 30
Study 11799082 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 28
Study 11799082 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 28
Study 10529261 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated limb perfusion (ILP) with melphalan
Number of subjects: 65
Study 10529261 — intervention group
Group type: COMPARATOR
Intervention: Wide excision only
Number of subjects: 65
Study 7793541 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 0
Study 7793541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study 7793541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 0
Study 1522839 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of mifepristone
Number of subjects: 800
Study 1522839 — intervention group
Group type: COMPARATOR
Intervention: 100 micrograms of ethinyl estradiol and 1 mg of norgestrel (standard therapy)
Number of subjects: 800
Study 6398430 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (30 mg/kg body weight/day for 1 week every 3 months)
Number of subjects: 40
Study 6398430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg twice/wk orally)
Number of subjects: 40
Study 31817691 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based protein blend #1
Number of subjects: 18
Study 31817691 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based protein blend #2
Number of subjects: 18
Study 31817691 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based protein blend #3
Number of subjects: 18
Study 31817691 — intervention group
Group type: COMPARATOR
Intervention: Whey Protein Isolate (WPI)
Number of subjects: 18
Study 29353627 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 60
Study 29353627 — intervention group
Group type: COMPARATOR
Intervention: Control (no reflexology)
Number of subjects: 60
Study 26950347 — intervention group
Group type: EXPERIMENTAL
Intervention: EBIKE training
Number of subjects: 12
Study 26950347 — intervention group
Group type: COMPARATOR
Intervention: Run training
Number of subjects: 12
Study 24970721 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0
Study 24970721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21883097 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (up to 4 mg/day, dosed once- or twice-daily) in study 206
Number of subjects: 201
Study 21883097 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (up to 12 mg/day, once-daily) in study 208
Number of subjects: 201
Study 21883097 — intervention group
Group type: COMPARATOR
Intervention: Placebo in study 206
Number of subjects: 201
Study 21883097 — intervention group
Group type: COMPARATOR
Intervention: Placebo in study 208
Number of subjects: 201
Study 20573972 — intervention group
Group type: EXPERIMENTAL
Intervention: LICI applied to the left DLPFC in 30 subjects
Number of subjects: 36
Study 20573972 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS-EEG indices of CI
Number of subjects: 36
Study 20573972 — intervention group
Group type: COMPARATOR
Intervention: EEG measures of LICI
Number of subjects: 36
Study 18156659 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein enriched recovery feeding (218 g protein, 435 g carbohydrate, 79 g fat)
Number of subjects: 10
Study 18156659 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control (34 g protein, 640 g carbohydrate, 79 g fat)
Number of subjects: 10
Study 16299640 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatrist telephone advice
Number of subjects: 669
Study 16299640 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 669
Study 11898004 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 560
Study 11898004 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 560
Study 11898004 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate ointment
Number of subjects: 560
Study 11898004 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment and 0.1% tacrolimus ointment
Number of subjects: 560
Study 11898004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus treatment groups
Number of subjects: 560
Study 10202314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-powder inhaler (DPI) with 200 microg salbutamol
Number of subjects: 10
Study 10202314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-powder inhaler (DPI) with 1,000 microg salbutamol
Number of subjects: 10
Study 10202314 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with spacer and 1,000 microg salbutamol
Number of subjects: 10
Study 10202314 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer (NEB) with 1,000 microg salbutamol
Number of subjects: 10
Study 10202314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7554879 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading by 5 dermatologists
Number of subjects: 40
Study 2157469 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 10 mg t.i.d. for six weeks
Number of subjects: 18
Study 2157469 — intervention group
Group type: COMPARATOR
Intervention: tiapamil 300 b.i.d. for six weeks
Number of subjects: 18
Study 7288605 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.2, 0.4 and 0.8 mg)
Number of subjects: 6
Study 7288605 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5 and 10 mg)
Number of subjects: 6
Study 31276585 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐18
Number of subjects: 0
Study 31276585 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2rα and IL‐6R
Number of subjects: 0
Study 27685251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting with lifestyle and diet advice (LFDA)
Number of subjects: 274
Study 27685251 — intervention group
Group type: COMPARATOR
Intervention: LFDA only (Control)
Number of subjects: 274
Study 27685251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting with LFDA
Number of subjects: 274
Study 27093204 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC Hydrogel (0.8 mg MMC with 1cc water and propylene glycol)
Number of subjects: 40
Study 24361227 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and gemcitabine (PG) chemotherapy
Number of subjects: 324
Study 24361227 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC28A3 SNP (rs7867504, C/T)
Number of subjects: 324